drugset / Trial / NCT00051298

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

NCT00051298

Phase 3 Completed 107 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of schizophrenia in adolescents. Both the potential benefits and side effects of olanzapine will be evaluated throughout this trial.

Timeline

Start
2002-11
Primary completion
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 2.5 mg
Subject Olanzapine Small molecule 20 mg

Indications